Group IIA Secretory Phospholipase A 2 , Vascular Inflammation, and Incident Cardiovascular Disease

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

(2018) Paul M Ridker et al.   LANCET

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease

(2016) Fabrizio Giordanetto et al.   ACS Medicinal Chemistry Letters

Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease

(2014) Nhat D. Quach et al.   BIOCHEMICAL PHARMACOLOGY

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome

(2014) Michelle L. O’Donoghue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome

(2014) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Proteolysis of Apolipoprotein A-I by Secretory Phospholipase A2

(2014) Giorgio Cavigiolio et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Expression of Type IIA Secretory Phospholipase A 2 Inhibits Cholesteryl Ester Transfer Protein Activity in Transgenic Mice

(2013) Eva Hurt-Camejo et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Group X Secreted Phospholipase A2 Limits the Development of Atherosclerosis in LDL Receptor–Null Mice

(2013) Hafid Ait-Oufella et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy

(2013) Samia Mora et al.   CIRCULATION

Secretory Phospholipase A 2 -IIA and Cardiovascular Disease

(2013) Michael V. Holmes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Phospholipase A 2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes

(2012) Sung Kee Ryu et al.   CIRCULATION

Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction

(2012) Daniel I. Chasman et al.   Circulation-Cardiovascular Genetics

Phospholipase A2 enzymes and the risk of atherosclerosis

(2012) R. S. Rosenson et al.   EUROPEAN HEART JOURNAL

On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy

(2012) Samia Mora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention

(2011) Edward A. Dennis et al.   CHEMICAL REVIEWS

GCTA: A Tool for Genome-wide Complex Trait Analysis

(2010) Jian Yang et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Lipoprotein-Associated and Secreted Phospholipases A 2 in Cardiovascular Disease

(2010) Ziad Mallat et al.   CIRCULATION

Lipoprotein modification by secretory phospholipase A2 enzymes contributes to the initiation and progression of atherosclerosis

(2009) Katariina Öörni et al.   CURRENT OPINION IN LIPIDOLOGY

Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease

(2009) W. Koenig et al.   EUROPEAN HEART JOURNAL

Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes

(2009) Robert S. Rosenson et al.   Current Cardiology Reports

Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis

(2008) E. Ibeas et al.   CARDIOVASCULAR RESEARCH

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE